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1 We have compared the binding properties of several hexocyclium and sila-hexocyclium derivatives to 
muscarinic Ml receptors (in rat brain, human neuroblastoma (NB-OK I) cells and calf superior cervical 
ganglia), rat heart M2 receptors, rat pancreas M3 receptors and M4 receptors in rat striatum, with their 
functional antimuscarinic properties in rabbit vas deferens (Ml/M4-like), guinea-pig atria (M2), and 
guinea-pig ileum (M3) muscarinic receptors. 
2 Si la-substitution (C/Si exchange) of hexocyclium (~ sila-hexocyclium) and demethyl-hexocyclium (~ 
demethyl-sila-hexocyclium) did not significantly affect their affinities for muscarinic receptors. By 
contrast, si la-substitution of o-methoxy-hexocyclium increased its affinity 2 to 3 fold for all the 
muscarinic receptor subtypes studied. 
3 The p-fluoro- and p-chloro-derivatives of sila-hexocyclium had lower affinities than the parent 
compound at the four receptor subtypes, in binding and pharmacological studies. 
4 In binding studies, o-methoxy-sila-hexocyclium (Ml = M4 ~ M3 ~ M2) had a much lower affinity than 
sila-hexocyclium for the four receptor subtypes, and discriminated the receptor subtypes more poorly 
than sila-hexocyclium (Ml = M3> M4> M2)' This is in marked contrast with the very clear selectivity of 
o-methoxy-sila-hexocyclium for the prejunctional MtlM4-like heteroreceptors in rabbit vas deferens. 
5 The tertiary amines demethyl-hexocyclium, demethyl-sila-hexocyclium and demethyl-o-methoxy-sila-
hexocyclium had 10 to 30 fold lower affinities than the corresponding quaternary ammonium derivatives. 
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Introduction 
Following the discovery that pirenzepine is able to dis-
criminate several muscarinic receptor binding sites (Hammer 
et al., 1980), the subclassification and characterization of 
various muscarinic receptor subtypes has aroused increasing 
interest. Molecular biology studies suggest that at least five 
genes encoding muscarinic receptor subtypes (ml-m5) are 
expressed in mammalian tissues (see Hulme et al., 1990; 
Levine & Birdsall, 1993). Functional and binding experiments 
revealed the existence of four different native subtypes, 
termed Ml- M4. Comparison of the radioligand binding pro-
perties and functional coupling of the native Ml-M4 recep-
tors with those of the expressed ml-m4 proteins showed a 
good correlation (Hulme et al., 1990; Lazareno et al., 1990; 
Waelbroeck et al., 1990; Dorje et al., 1991; Levine & Birdsall, 
1993). 
Although several drugs have been reported to discriminate 
the Ml from M2, M3 and M. receptors in binding and/or 
functional studies, most of these drugs possess tertiary amino 
groups. Their binding properties, like those of pirenzepine, 
might therefore be strongly pH-dependent (Barlow & Chan, 
1982), a factor which may complicate the identification of 
receptor sUbtypes. It was interesting, therefore, that a quater-
nary ammonium compound, o-methoxy-sila-hexocyclium, 
was found to have very clear Ml selectivity in functional 
studies (Lambrecht et al., 1988; Boddeke et al., 1989; Polidori 
et al., 1990). 
The goal of the present study was to evaluate the struc-
tural requirements for binding of the carbon/silicon 
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analogues hexocyclium and sila-hexocyclium and related 
compounds (Figure 1) to Mlo cardiac M2, glandular/smooth 
muscle M3 and brain M4 sites. To achieve this goal, we 
analysed the binding properties of the compounds to PH]-
pirenzepine-Iabelled Ml sites in rat brain cortex, PH]-
telenzepine-Iabelled Ml sites in calf superior cervical ganglia 
(Feifel et al., 1991) or [3H]-N-methyl-scopolamine ([3H]_ 
NMS)-Iabelled NB-OK I (Ml) sites (Waelbroeck et al., 
1987b; 1988), [3H]-NMS-labelled rat cardiac M2 sites (Wael-
broeck et al., 1987a), PH]-NMS-Iabelled rat pancreas M3 
sites (Waelbroeck et al., 1987a) and [3H]-NMS-labelled M4 
sites in rat striatum, sites with a slow dissociation rate for 
NMS (Waelbroeck et al., 1987b; 1990). 
We compared the binding affinity profiles at these four 
receptor subtypes with the pharmacological properties of the 
compounds at prejunctional muscarinic heteroreceptors in 
rabbit vas deferens (Eltze, 1988; Eltze et al., 1988; Grimm et 
al., 1994; Lambrecht et al., 1993), M2 receptors in guinea-pig 
atria, and M3 receptors in guinea-pig ileum (see review by 
Caulfield, 1993). 
The affinities of a number of antagonists for the prejunc-
tional muscanmc receptors mediating inhibition of 
neurogenic contractions of rabbit vas deferens clearly 
indicate that these receptors are not the M2, M3 or m5 
subtype (Eltze, 1988; Eltze et aI., 1988; 1993; Lambrecht et 
al., 1989; Dorje et al., 1991; Grimm et al., 1994). The most 
prominent features of these prejunctional inhibitory receptors 
are: (i) a high affinity for the Ml-selective antagonist 
pirenzepine (pA2 values = 8.08-8.52; Lambrecht et al., 1989; 
Choo & Mitchelson, 1990; Micheletti et al., 1990a; Dorje et 
al., 1990; Eltze et al., 1993; Sagrada et al., 1993); (ii) a high 
affinity for the M2/M4-selective antagonist himbacine (pA2 
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values = 8.5-8.17; Dorje et al., 1990; Eltze et al., 1993; Sag-
rada et al., 1993); and (iii) a low affinity for methoctramine 
(pA2 value = 6.85; Lambrecht et al., 1989). It is also worth 
noting that there is immunoreactivity to specific anti-m 1 
receptor antibodies, but not to anti-m4 antibodies, in rabbit 
vas deferens (Dorje et al., 1991). Thus, we are left with 
arguments for and against the presence of inhibitory mus-
carinic Ml and M4 heteroreceptors in rabbit vas deferens. 
Perhaps the data may be reconciled by multiple, Ml and M4, 
prejunctional muscarinic receptors. 
Further experiments are needed to clarify this issue. To 
reflect this lack of final definition of the prejunctional rabbit 
vas deferens receptor subtype, in this paper we will use the 
term MdM4-like for these receptors. 
Preliminary accounts of this study have been com-
municated to the German Society for Pharmacology and 
Toxicology, Hamburg, September 1988 (Mutschler et al., 
1988) and to the IUPHAR, Amsterdam, July 1990 (Feifel et 
al., 1990). 
Methods 
Radioligand binding experiments: general considerations 
Protein concentrations were determined according to Lowry 
et al. (1951), using bovine serum albumin as standard. Male 
Wistar albino rats were killed by decapitation and the brain, 
heart or pancreas immediately removed. Calf superior cer-
vical ganglia were obtained from a regional slaughterhouse 
and brought into the laboratory within 70 min. NB-OK 1 
cells were cultured as previously described (Waelbroeck et al., 
1988), in RPMI 1640 medium enriched with 10% foetal calf 
serum, 100 units ml- 1 penicillin and 100 I1g ml- 1 strep-
tomycin. All the following operations were performed at 4·C. 
Preparation of the homogenates or crude membranes 
used for binding studies 
M J receptors For [3HJ-NMS binding experiments, the NB-
OK 1 cells were rinsed, harvested and centrifuged in 20 mM 
sodium phosphate buffer (pH 7.4) containing 150 mM NaCl 
and 1 mM EDT A, resuspended and homogenized in 20 mM 
Tris/HCI buffer (pH 7.5) enriched with 5 mM MgCh and 
stored in liquid nitrogen. 
The rat brain cortex was homogenized in 15 ml of 20 mM 
Tris/HCl buffer (PH 7.5) enriched with 250 mM sucrose, in a 
glass-teflon homogenizer (7 up and down strokes). The re-
sulting homogenate was stored in liquid nitrogen until use, 
and diluted 5 fold with the same buffer immediately before 
the experiment. 
After separation of surrounding tissue, the calf superior 
cervical ganglia were minced with scissors and homogenized 
in ice-cold buffer solution (30 g tissue wet weight/lOO ml of 
50 mM Tris/HCI buffer (pH 7.4) enriched with 120 mM NaCI 
and 5 mM MgCh), with an Ultra-Turrax (maximal speed, for 
2 x 30 s). The homogenate was centrifuged at 160 g for 
10 min, and the pellet was ground a second time and pro-
cessed as before. The supernatants were combined and cen-
trifuged for I h at 100,000 g. The pellets (corresponding to 
20% of the original wet weight of the original tissue) were 
stored at - 20·C until use. For binding studies, the pellets 
were resuspended in ice-cold buffer with a Potter-Elvejhem 
homogenizer. 
M2 receptors The rat heart was rinsed in isotonic NaCl, 
then homogenized in 2.5 ml of 20 mM Tris/HCI buffer 
(pH 7.5), enriched with 250 mM sucrose, with an Ultra-
Turrax (maximal speed, for 5 s) followed by addition of 
12.5 ml of the same buffer, 7 up and down strokes with a 
glass-teflon homogenizer and filtration on 2 layers of medical 
gauze. 
M3 receptors The rat pancreas was minced with scissors and 
homogenized with a glass-teflon homogenizer (7 up and 
down strokes) in 8 ml of 300 mM sucrose enriched with 
0.2 mg ml- 1 bacitracin and 500 kallikrein inhibitor units 
(KIU) ml- 1 of trasylol. The resulting homogenate was 
immediately filtered over two layers of medical gauze and 
diluted 11 fold with the incubation buffer (66 mM sodium 
phosphate buffer, pH 7.4, enriched with 2.6 mM MgCh and 
with 13 mgml- 1 bovine serum albumin, 0.24mgml- 1 baci-
tracin and 600 KIU ml- 1 of trasylol). 
M4 receptors Rat striatum homogenates were prepared in 
2 ml of 20 mM Tris/HCI buffer (pH 7.5), enriched with 
250 mM sucrose, and stored in liquid nitrogen until use. The 
homogenates were diluted 20 fold with the homogenization 
buffer, immediately before the incubation with fH]-NMS. 
Binding studies 
Most binding studies were performed at 25T, at equilibrium, 
in a 50 mM sodium phosphate buffer (pH 7.4) enriched with 
2 mM MgCI2 and 1 % bovine serum albumin (and, for 
incubations with pancreas, 0.2 mg ml- 1 bacitracin and 500 
KIU ml- 1 trasylol), [3H]_ NMS or [3H]-pirenzepine and the 
indicated unlabelled drugs concentrations, in a total volume 
of 1.2 ml. In contrast, [3H]-telenzepine binding studies were 
performed at 37"C, in a 50 mM Tris/HCI buffer enriched with 
120 mM NaCI, 5 mM MgCI2, [3H]-telenzepine, and the 
indicated unlabelled drugs concentrations, in a total volume 
of 350111. 
To measure fH]-pirenzepine binding to brain cortex 
homogenates, we used 80111 of the homogenate, correspon-
ding to a protein concentration of 200l1g per assay. A 2 h 
incubation allowed equilibrium binding. The fH]-pirenzepine 
concentration was 5 nM. To measure [3HJ-telenzepine binding 
to calf superior cervical ganglia, we used 250 111 of the 
homogenate (corresponding to 1.25 mg crude membrane wet 
weight). The [3H]-telenzepine concentration was 0.8 nM. A 
2 h incubation allowed equilibrium binding. To measure [3HJ-
NMS binding to NB-OK 1 homogenates, we used 80111 of 
homogenate, corresponding to about 200 I1g protein per 
assay. The incubation period was 2 h to achieve equilibrium 
binding in the presence of 0.25 nM [3H]-NMS. For incuba-
tions with rat heart homogenates, we used 80111 of the 
homogenate, corresponding to 400 to 500l1g protein per 
assay. The 2 h incubation period was sufficient to allow 
equilibrium binding. The fH]-NMS concentration used was 
1.0 nM. To analyse [3HJ-NMS binding to pancreas 
homogenates, we used 80 111 of homogenate, corresponding to 
800l1g pancreas protein per assay. A 4 h incubation period 
was necessary to allow full equilibration of [3HJ-NMS bind-
ing at 25·C. The tracer concentration used was 0.25 nM. In 
rat striatum homogenates, fHJ-NMS labels Mb very few M2 
and M3, and a majority of M4 sites. It dissociates faster from 
the Ml and M2 sites. (Waelbroeck et al., 1987b; 1990). We 
preincubated 80111 of the homogenate (equivalent to about 
30 I1g protein) in a total volume of 1.2 ml, in the presence of 
[3HJ-NMS and unlabelled drugs. A 2 h preincubation period 
allowed equilibrium binding. We then added II1M atropine 
and allowed tracer dissociation for 35 min before filtration. 
This procedure allowed us to investigate tracer binding to the 
striatum M4 sites. The tracer concentration used in these 
experiments was 0.25 nM. 
The incubations were stopped by addition of 2 ml ice-cold 
filtration buffer (50 mM sodium phosphate buffer, pH 7.4). 
Bound and free tracer were immediately separated by filtra-
tion on glass fibre GFC filters presoaked overnight in 0.05% 
polyethyleneimine. The samples were rinsed three times with 
filtration buffer. The filters were then dried, and the bound 
radioactivity counted by liquid scintillation. Non specific 
[3HJ-telenzepine, fHJ-NMS or fH]-pirenzepine binding was 
defined as tracer bound in the presence of 10 I1M atropine. 
For more experimental details, see Waelbroeck et al. 
(1987a,b; 1988; 1990) and Feifel et al. (1991). 
Analysis of binding data 
All competition curves were repeated three times in duplicate. 
ICso values were determined by a computer-aided procedure 
described by Richardson & Humrich (1984), assuming the 
existence of only one receptor sUbtype. Ki values were deter-
mined from IC50 values by the Cheng & Prusoff (1973) 
equation, using the radio ligand Ko values obtained in the 
same tissue. The p~ values shown in Table 1 correspond to 
- log ~ values. 
The standard deviations of p~ values were equal to or 
below 0.1 log unit. 
Pharmacological experiments 
Rabbit vas deferens Male New Zealand white rabbits 
(2.5-3.0 kg) were killed by i.v. injection of 120 mg kg-\ pen-
tobarbitone sodium. The vasa deferentia were excised, 
dissected free of connective tissue and divided into four 
segments of approximately 1.5 cm length. The preparations 
were set up in 7 ml organ baths containing modified Krebs 
buffer which consisted of (mM): NaCl 118, KCl 4.7, CaCl2 
2.5, MgS04 0.6, KH2P04 1.2, NaHC03 25.0 and ( + )-glucose 
11.1; I/lM yohimbine was included to block Clz-adreno-
ceptors. The bathing fluid was maintained at pH 7.4, 31 DC, 
and aerated with 95% 0 2/5% CO2. A basal tension of 
750 mg was applied. After a 30 min equilibration period, 
isometric twitch contractions were elicited by electrical field 
stimulation (0.05 Hz, 0.5 ms, 30 V) with platinum electrodes. 
These effects were concentration-dependently inhibited by the 
M\ receptor agonists 4-(3-chlorophenylcarbamoyloxy)-2-buty-
nyltrimethylammonium chloride (McN-A-343) and 4-(4-chlor-
ophenylcarbamoyloxy)-2-butynyltrimethylammonium iodide 
(4-Cl-McN-A-343) (Eltze, 1988; Eltze et al., 1988; Boddeke, 
1991; Lambrecht et al., 1993). The neurogenic contractions 
were measured by a force-displacement transducer connected 
to a Hellige amplifier and a Rikadenki polygraph. 
Guinea-pig atria and ileum Adult guinea-pigs of either sex 
were killed by cervical dislocation and the organs required 
were removed. Left atria and strips of ileal longitudinal 
smooth muscle of 1.5 cm length (Paton & Zar, 1968) were set 
up in 6 ml organ baths, under 500 mg tension, in oxygenated 
(95% 0 2/5% CO2) Tyrode solution, composed of (mM): 
NaCl 137, KCl 2.7, CaCh 1.8, MgCh 1.05, NaHC03 11.9, 
NaH2P04 0.42 and (+ )-glucose 5.6. All experiments were 
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conducted at 32"C (PH 7.4). The agonist used was arecaidine 
propargyl ester (Mutschler & Lambrecht, 1984; Barlow & 
Weston-Smith, 1985; Lambrecht et al., 1993). 
Left atria were electrically paced by means of platinum 
electrodes (2 Hz, 3 ms duration, supramaximal Voltage). 
Atrial responses to the agonist were measured as changes in 
isometric tension, and these effects were expressed as the 
percentage inhibition of the force of contraction. Responses 
of ileal longitudinal smooth muscle strips to arecaidine pro-
pargyl ester were measured as isotonic contractions. The 
effects in atria and ileum were recorded as with the rabbit vas 
deferens. 
Antagonist affinities 
After 1 h equilibration, concentration-response curves were 
obtained by cumulative addition of the agonists (Van Ros-
sum, 1963). When these responses were constant, 
concentration-response curves were repeated in the presence 
of at least 3 concentrations (in most cases, log inter-
val = 0.48) of antagonists, allowing 15-45 min equilibration 
time. Each concentration of antagonist was tested 3 to 5 
times and the ratios of agonist molar EC50 values obtained in 
the presence and absence of antagonists were calculated. The 
slopes of the Arunlakshana-Schild plots (Arunlakshana & 
Schild, 1959) were determined by linear regression using the 
method of least squares. pA2 values were estimated by fitting 
to the data the best straight line with a slope of unity 
(Arunlakshana & Schild, 1959; Tallarida et al., 1979). 
To assess whether o-methoxy-sila-hexocyclium (3b) had 
actions at a site in addition to that occupied by the M\-
selective agonist, McN-A-343, in rabbit vas deferens, com-
bination antagonist studies were performed on the basis of 
dose-ratio analysis (Paton & Rang, 1965). The concentration-
response curves to McN-A-343 in these experiments were 
obtained under control conditions and then in the presence 
of compound 3b (50/lM) or pirenzepine (50/lM) alone or 
with the two antagonists combined. The contact time for 
pirenzepine and 3b was always 30 min. The experimental 
data for individual antagonist applications were used to cal-
culate dose-ratios (DR) expected for the combination for two 
models: expected single-site = DR\ + DR2 - 1 and expected 
independent sites = DR\ x DR2. These dose-ratios were com-
pared with the experimentally observed combined mean dose-
ratio. 
Data analysis 
All data are presented as means ± s.e.mean of the indicated 
number (n) of experiments. Linear regression analyses were 
Table I pKi values obtained in binding studies on NB-OK 1 cells, rat brain cortex and calf superior cervical ganglia (CSCG; M\ 
sites), rat heart (M2 sites), rat pancreas (M3 sites) and to the slowly-dissociating (M4) sites in rat striatum" 
M] M] M3 M4 
Antagonist NB-OK 1 Cortex CSCG Heart Pancreas Striatum 
la Hexocycliumb 8.8 8.9c 7.7 8.4 8.8 
Ib Sila-hexocycliumb 8.9 8.8C 8.9 7.6 8.4 8.8 
2a Demethyl-hexocycliumb 8.0 8.0 6.7 7.4 8.0 
2b Demethyl-sila-hexocycliumb 7.9 7.9 6.6 7.4 8.0 
3a o-Methoxy-hexocyclium 6.8 6.8 5.9 6.2 6.8 
3b o-Methoxy-sila-hexocyclium 7.1 7.1 6.9 6.3 6.6 7.0 
4 Demethyl-o-methoxy-sila-hexocyclium 6.5 6.4 6.7 5.3 5.6 6.2 
5 p-Fluoro-sila-hexocyclium 7.9 7.9 7.8 6.9 7.3 7.9 
6 p-Chloro-sila-hexocyclium 7.4 7.5 7.4 6.4 7.0 7.1 
"The standard deviations of the pKi values were typically ± 0.1 log unit, always below 0.15 log unit. The Hill coefficients varied 
between 0.95 and 1.05 (standard deviation ± 0.1) except for the [3Hl-pirenzepine/la/lb competition curves in brain cortex (Hill 
coefficients of 0.85 were obtained for these compounds). 
bThe pKi values of these compounds in NB-OK 1 cells, pancreas and heart homogenates have been published previously (Waelbroeck 
et al., 1989). 
cThe competition curves were biphasic (see text). The pKi values indicated correspond to the major 'subclass' of binding sites (85 to 
90% of tracer binding). 
508 M. WAELBROECK et al. 
carried out by the method of least squares (Tallarida et ai., 
1979). Differences between mean values were tested for statis-
tical significance by Student's t test; P<0.05 was accepted as 
being significant. 
Compounds 
fH]-N-methylscopolamine methyl chloride ([3H]-NMS, 80 to 
85 Ci mmol- 1) was obtained from Amersham International 
(Bucks, England). [3H]-pirenzepine (80 to 85 Ci mmol- 1) was 
from New England Nuclear, Boston, MA, U.S.A. Racemic 
[3H]-telenzepine (85 Ci mmol- 1) was a generous gift from Byk 
Gulden Lomberg, Konstanz, Germany, 4-(3-chlorophenyl-
carbamoyloxy)-2-butynyltrimethylammonium chloride (McN-
A-343), atropine sulphate, bovine serum albumin (Fraction 
V) and polyethyleneimine were from Sigma Chemical Co. (St 
Louis, MO, U.S.A.), and glass fibre filters GFC from What-
mann (Maidstone, England). All other reagents were of the 
highest grade available. Pirenzepine dihydrochloride was a 
generous gift from Thomae (Biberach, Germany). 4-(4-
Chlorophenylcarbamoyloxy)-2-butynyltrimethylammonium iod-
ide (4-CI-McN-A-343; Nelson et ai., 1976), arecaidine propargyl 
ester (Mutschler & Hultzsch, 1973), hexocyclium (la; as 
methyl sulphate; Zaugg et ai., 1958), sila-hexocyclium (Ib as 
methyl sulphate; Tacke et al., 1989a), demethyl-hexocyclium 
(2a; Zaugg et al., 1958), demethyl-sila-hexocyclium (2b; as 
dihydrochloride), o-methoxy-hexocyclium (3a; as methyl sul-
phate; Strohmann, 1990), o-methoxy-sila-hexocyclium (3b; as 
methyl sulphate; Tacke et al., 1 989b) and demethyl-o-
methoxy-sila-hexocyclium (4; as dihydrochloride; Tacke et 
ai., 1989b) were synthesized in our laboratories according to 
the literature. p-Fluoro-sila-hexocyclium (5; as methyl sul-
phate; m.p. 108°C) and p-chloro-sila-hexocyclium (6; as 
methyl sulphate; m.p. 149-150°C) were prepared by analogy 
to the parent compound sila-hexocyclium (Ib; Tacke et al., 
1989b). Compounds 5 and 6 were characterized by IH-NMR, 
Q /OH 
U
C
, 1\ /CH 3 
'CH -N N/(±) 
2 '-....I "CH,) 
70 
4 
13C-NMR and El-MS measurements as well as by elemental 
analyses. 
Compounds la/lb-3a/3b and 4-6 (see Figure I) possess a 
centre of chirality, the carbinol and silanol, respectively, car-
bon and silicon atom, and therefore exist in two enantiomers. 
In this study, all compounds were used as racemates. 
Results 
Radioligand binding studies 
All compounds inhibited tracer binding to muscarinic recep-
tors. Most competition curves did not deviate significantly 
from results expected for competitive inhibition of tracer 
binding to a single receptor (see for example Figures 2 and 
3). The only exceptions to this rule were the [3H]-pirenzepine/ 
hexocyclium (la) and [lH]-pirenzepine/sila-hexocyclium (Ib) 
competition curves in rat cortex (Figure 2): these two quater-
nary compounds inhibited [3H]-pirenzepine binding to 85 or 
90% of the receptors with a high affinity, and to 10 or 15% 
of the receptor with a very low affinity (Figure 2). However, 
the affinities of compounds la/lb-3a/3b and 4-6 for the 
majority of Ml receptors in rat cortex were very similar to 
that for Ml receptors in NB-OK 1 cells and calf superior 
cervical ganglia (Table I, Figures 2 and 3). The structure-
affinity relationships of the hexocyclium and sila-hexocyclium 
derivatives at each receptor subtype are summarized in Table 
1 and Figure 4. 
The hexocyclium and sila-hexocyclium derivatives studied 
in this work, like the parent compounds hexocyclium and 
sila-hexocyclium, had a clear preference for M1, M3 and M4 
over M2 receptors (Table 1). The same affinity. profile 
(Ml ~M3~M4> M2) has been reported for hexocyclium as 
well as for sila-hexocyclium at cloned muscarinic ml-~ 
receptors expressed in CHO-Kl cells (Buckley et ai., 1989). 
Figure I Structural formulas of the compounds studied: hexocyclium (la) and sila-hexocyc1ium (Ib), demethyl-hexocyclium (2a) 
and demethyl-sila-hexocyc1ium (2b), o-methoxy-hexocyc1ium (3a) and o-methoxy-sila-hexocyc1ium (3b), demethyl-o-methoxy-sila-
hexocyc1ium (4), p-fluoro-sila-hexocyc1ium (5) and p-chloro-sila-hexocyc1ium (6). All compounds possess a centre of chirality and 
therefore exist in two enantiomers. In this study, they were used as racemates. 
Pharmacological studies 
All compounds antagonized the inhibition of neurogenic con-
tractions of rabbit vas deferens by McN-A-343 or 4-CI-McN-
A-343 as well as the negative inotropic effects in electrically 
stimulated guinea-pig left atria and the contractions of the 
guinea-pig ileum to arecaidine propargyl ester. This is shown 
for o-methoxy-sila-hexocyclium (3b) in Figure 5. With the 
exception of demethyl-o-methoxy-sila-hexocycliurn (4) in 
atria (Table 2), there was a concentration-dependent parallel 
shift to the right of agonist dose-response curves without 
either the basal tension or the maximal responses being 
affected. The Schild plots were linear throughout the 
100 -,: 
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:J 
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Cl 
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.0. 
Cl 
N 50 c 
Cl 
.... 
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Flpre 2 [3H]-pirenzepine competitIOn curves in rat cortex were 
obtained as explained in Methods, using la or Ib (e) (the experi-
mental data were within 2% of the means; we therefore used a single 
symbol for the two compounds), 3a (Ll) and 3b (.&). 
1:l 
C 
:J 
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O~I~--~----~--~~~~~~ 
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[o-Methoxy-sila-hexocyclium (3b)] (log M) 
Fi&ure 3 Com~etition curves obtained at four muscarinic receptor 
subtypes: (a) [H]-NMS/sila-hexocyclium (Ib) competition curves 
were obtained as explained in Methods, using NB-OK I cells (0), 
heart (e), pancreas (Ll) or striatum M4 (x) sites. (b) [3H]-NMS/o-
methoxy-sila-hexocyclium (3b) competition curves were obtained as 
explained in Methods, using NB-OK I cells (0), heart (e), pancreas 
(Ll), or striatum M4 (x) sites. 
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antagonist concentration-range studied, and slopes were not 
significantly different from unity (P> 0.05), except for 0-
methoxy-sila-hexocyclium (3b) at M2 receptors (Figure 5 and 
Table 2). The pA2 value of 3b in guinea-pig atria (6.41) might 
therefore be regarded as a purely experimental quantity. 
However, the binding affinity of 3b to M2 receptors in rat 
heart (pKi = 6.3; Table 1) was very similar to that obtained in 
functional studies in guinea-pig atria. In the radioligand bin-
ding studies (Figure 3), competition curves with 3b in rat 
heart homogenates did not deviate significantly from results 
expected for competitive inhibition of [3H]-NMS binding at a 
single binding site. Thus, compounds la/lb-3a/3b and 4-6 
were apparently simple competitive antagonists in the 
preparations studied. The pA2 values are shown in Table 2. 
Hexocyclium (la), sila-hexocyclium (lb) and the 
derivatives studied in this work had a greater affinity for the 
MdM4-like heteroreceptors in rabbit vas deferens as com-
pared to guinea-pig (M2) receptors (Table 2). Most of the 
compounds also had a higher affinity for guinea-pig ileum M3 
receptors (Table 2). o-Methoxy-sila-hexocyclium (3b) had a 
different selectivity pattern: it had a 30 fold and 100 fold 
higher affinity for MdM4-like receptors in rabbit vas deferens 
over M3 receptors in guinea-pig ileum and M2 receptors in 
guinea-pig atria, respectively (Table 2). 
To investigate whether o-methoxy-sila-hexocyclium (3b) 
was interacting solely at the muscarinic receptor in rabbit vas 
deferens occupied by the agonist McN-A-343, combination 
concentration-ratio experiments were undertaken with 
pirenzepine using the method of Paton & Rang (1965). 
The concentration-ratios, determined in separate tissues 
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Figure 4 Structure-activity relationships for binding of compounds 
structurally related to hexocyclium (hatched columns) or to sila-
hexocyclium (open columns). The receptors investigated were: NB-
OK-I receptors (M 1) (a); rat heart (M2) (c); rat pancreas (M3) (d); 
and M4 in rat striatum (b). The compounds were: hexocyclium and 
sila-hexocyclim (I, open and hatched bars), demethyl-hexocyclium 
and demethyl-sila-hexocyclium (2, open and hatched bars), 0-
methoxy-hexocyclium and o-methoxy-sila hexocyclium (3, open and 
hatched bars), demethyl-o-methoxy-sila-hexocyclium (4), p-fluoro-
sila-hexocyclium (5) and p-chloro-sila-hexocyclium (6). Their pKi 
values at the four muscarinic receptor subtypes were measured as 
explained in Methods. 
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Table 2 Affinity profiles of hexocyclium, sila-hexocyclium and related muscarinic antagonists at muscarinic Mt/M4-like receptors in 
rabbit vas deferens, M2 receptors in guinea-pig atria, and M3 receptors in guinea-pig ileum 
M J/M4-Iike M] M3 
Rabbit vas Guinea-pig Guinea-pig 
Antagonist deferens atria ileum 
la Hexocyclium 8.89 ± 0.03 7.75 ± 0.03" 8.49 ± 0.04" 
(1.03 ± 0.07) (0.97 ± 0.06) (1.05 ± 0.07) 
Ib Sila-hexocyclium 9.01 ± 0.Q7 7.57 ± 0.04" 8.78 ± 0.05" 
(1.04 ± 0.09) (0.94 ± 0.07) (1.04 ± 0.09) 
2a Demethyl-hexocyclium 7.69 ± 0.06 6.51 ± 0.08" 7.63 ± 0.03" 
(0.94 ± 0.11) (1.05 ± 0.09) (1.08 ± 0.06) 
2b Demethyl-sila-hexocyclium 7.73 ± 0.12 6.65 ± 0.04" 7.87 ± 0.04" 
(1.11 ± 0.09) (1.02 ± 0.11) (0.94 ± 0.08) 
3a o-Methoxy-hexocyclium 7.23 ± 0.04 6.18 ± 0.05 6.77 ± 0.02 
(0.95 ± 0.12) (0.89 ± 0.10) (1.07 ± 0.04) 
3b o-Methoxy-sila-hexocyclium 8.39 ± 0.05 6.41 ± O.Olb 6.96 ± 0.03b 
(1.01 ± 0.09) (1.25 ± 0.06)" (0.93 ± 0.06) 
4 Demethyl-o-methoxy-sila-hexocyclium 6.44 ± 0.06 5.51 ± 0.03d 6.36 ± 0.04 
(1.11 ± 0.14) (0.93 ± 0.06) 
5 p-Fluoro-sila-hexocyclium 8.32 ± 0.Q7 7.40 ± 0.04 8.25 ± 0.06 
(1.04 ± 0.14) (0.92 ± 0.07) (0.99 ± 0.10) 
6 p-Chloro-sila-hexocyclium 7.79 ± 0.04 6.93 ± 0.Q2 7.67 ± 0.04 
(0.98 ± 0.07) (1.00 ± 0.03) (1.07 ± 0.06) 
pA2 values and slopes of Schild plots (in parentheses) are presented as means ± s.e.mean (n = 3-5). 
"Data taken from Waelbroeck et al. (1989). 
bData taken from Lambrecht et al. (1988). 
CSignificantly different from unity (P < 0.05). dOnly one concentration (10 I'M: n = 5) was investigated due to the negative inotropic 
effects of the compound itself at higher concentrations. The pA2 values were therefore determined from the individual dose-ratios 
according to Tallarida et al. (1979). 
(n = 5) for pirenzepine (50 nM; DR, = 11.8 ::t 1.5, pA2 = 
8.32 ± 0.05) and compound 3b (50 nM; DR2 = 7.4 ± 0.6, 
pA2 = 8.10 ± 0.01) were first ascertained. Again, in separate 
tissues (n = 5), the effect of compound 3b was determined in 
the presence of pirenzepine (DR = 18.3 ± 2.4). This com-
bined mean dose-ratio obtained experimentally was very 
close to that calculated for the two antagonists acting by 
competing with the agonist for the receptor site 
(DR, + DR2 - I = 19.2). The results were not consistent 
(P<0.05, unpaired t test) with a multiplication of dose-
ratios (DR, x DR2 = 87.0) which would be expected if the 
two antagonists interacted at independent sites. 
Discussion 
The native muscanmc receptors are currently divided, in 
binding and functional studies, into four subtypes (M1- M4), 
the M, receptors being recognized by their higher affinity for 
pirenzepine (see, Hulme et al., 1990; Wae1broeck et al., 1990; 
Lazareno et al., 1990; Dorje et al., 1991; Doods et al., 1993; 
Lazareno & Birdsall, 1993; Levine & Birdsall, 1993). 
As pointed out some years ago by Barlow & Chan (1982), 
the fact that pirenzepine is a tertiary amine may lead to 
problems in determining its antimuscarinic potency. Indeed, 
titration of the amino group of pirenzepine by variation of 
the pH of the bath fluid affects markedly its affinity for 
muscarinic receptors in smooth muscle (Barlow & Chan, 
1982). o-Methoxy-sila-hexocyclium (3b) is the first M,-
selective quaternary muscarinic antagonist in functional 
studies (Lambrecht et al., 1988; Boddeke et al., 1989; Polidori 
et al., 1990). It has a large functional M, > M3 selectivity, 
and an even greater M, > M2 selectivity than pirenzepine. 
With this in mind, we decided to measure its affinity for four 
muscarinic receptor subtypes, and to investigate the 
structure-activity relationships of various tertiary and quater-
nary hexocyclium and sila-hexocyclium derivatives (Figure 1) 
at different muscarinic receptor subtypes. These studies were 
also performed as a part of our systematic investigations on 
carbon/silicon bioisosterism (Tacke & Zilch, 1986; Tacke & 
Linoh, 1989; Wae1broeck et al., 1989). 
General considerations 
In functional experiments, hexocyclium, sila-hexocyclium and 
their derivatives behaved as competitive muscarinic 
antagonists (Figure 5 and Table 2). 
In binding studies, most of the competition curves were 
also compatible with competitive antagonism at a single site 
(Figures 2 and 3). Hexocyclium and sila-hexocyclium, how-
ever, recognized a small fraction (10-15%) of the [3H]_ 
pirenzepine-Iabelled receptors with a very low affinity (Figure 
2). We observed the same type of competition curves with 
other quaternary antagonists having a high affinity (results 
not shown), using either [3H]-quinuclidinyl benzylate or fHl-
pirenzepine as tracer, i.e. two tertiary amines. As demon-
strated by Ellis (1988), this population of receptors with very 
low affinity for quaternary antagonists is not correlated with 
the MJ, M2, M3 or M4 receptor category. We are not aware 
of the existence of muscarinic receptors having (in functional 
studies) a comparable affinity profile. We therefore believe 
that this reflects the existence of binding sites accessible only 
through a hydrophobic barrier (for instance facing inside 
closed vesicles) (see Ellis, 1988). 
Structure-activity relationships 
Sila-substitution of hexocyclium (la -+ lb) and demethyl-
hexocyclium (2a -+ 2b) increased only slightly their affinities 
for the different muscarinic receptor subtypes (Wae1broeck et 
al., 1989). The effect of sila-substitution on o-methoxy-
hexocyclium (3a -+ 3b) was somewhat greater (Figure 3a and 
Table 1). In binding studies, we observed a 2 to 3 fold greater 
affinity for 3b than for 3a, at all the muscarinic receptor 
subtypes (Table 1). In pharmacological studies, 3b had a 
15 fold higher affinity than 3a for the Mt/M4-like receptors in 
rabbit vas deferens (Table 2). 
Demethylation of hexocyclium (la -+ 2a), sila-hexocyclium 
(lb-+2b) and o-methoxy-sila-hexocyclium (3b-+4) decreased 
affinities for all muscarinic receptor subtypes by at least 
5 fold (Wae1broeck et al., 1989, and this work). This very 
large effect cannot be explained solely by the stabilization of 
the positive charge on the quaternary ammonium group, and 
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Figure 5 Antagonism of responses to McN-A-343 in rabbit vas 
deferens and to arecaidine propargyl ester in guinea-pig paced left 
atria and ileum by different concentrations of o-methoxy-sila-
; hexocyclium (3b). Data are means ± s.e.mean. Error bars falling 
. within the area covered by a symbol are not shown. (a) 
Concentration-response curves for McN-A-343-induced inhibition of 
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Figure 6 Comparison of the pKj and pA2 values of hexocyclium, 
sila-hexocyclium and related compounds. The pKj values obtained in 
NB-OK-l cells were compared to pA2 values in rabbit vas deferens 
(0), the pKj values obtained in rat heart with the pA2 values in 
guinea-pig atria (L:.) and the pKj values obtained in rat pancreas, 
with the pA2 values in guinea-pig ileum (e). The lines were obtained 
by linear regression of the data, excluding o-methoxy-sila-
hexocyclium (3b) on the Ml-MdM4-like receptors, andp-ftuoro-sila-
hexocyclium (5) on the M3 receptors. 
therefore suggests that this ammonium group fits in a hydro-
phobic pocket. 
Substitutions of the phenyl ring in the para-position (p-
fluoro- and p-chloro-derivatives, 5 and 6) and in the ortho-
position (o-methoxy derivatives, 3a, 3b and 4) decreased the 
affinities of the respective parent drugs la, Ib and 2b at the 
four muscarinic receptor subtypes (Figure 4). The affinity loss 
due to replacement of a hydrogen by a (small) fluorine atom 
varied between 5 and lO fold, depending on the receptor 
subtype studied. This suggested that the introduction of a 
fluorine atom not only induced steric repulsions between the 
phenyl group and the muscarinic binding site, but probably 
also modified the electronic properties of the whole phenyl 
ring (polarization), with unfavourable effects on the interac-
tion with the muscarinic receptors. 
In binding studies, the affinity loss due to introducing an 
o-methoxy group was very impressive (20 to 160 fold lower 
affinity). Binding to all subtypes was similarly affected by the 
modification (compare la-+3a, Ib-+3b, 2b-+4). In contrast, 
o-methoxy-sila-hexocyclium (3b) had a high potency in phar-
macological experiments at Ml receptors (pA2 value of 8.31 
in rat superior cervical ganglia, Lambrecht et aI., 1988; Bod-
deke et al., 1989) and at Mt/M4-like receptors in rabbit vas 
deferens (PA2 value = 8.39; this study). 
neurogenic twitch contractions in rabbit vas aeferens in the absence 
(.; n = 12) and presence (n = 4) of 5 (e), 15 (~), 45 (+) and 300 
(.6.) nM 3b. (b) Concentration-response curves for arecaidine propar-
gyl ester-induced negative inotropy in guinea-pig atria in the absence 
(.; n = 6) and presence (n = 3) of 1 (e), 3 (~) and 10 (+) I'M 3b. 
(c) Concentration-response curves for arecaidine propargyl ester-
induced contractions in guinea-pig isolated ileum longitudinal 
smooth muscle in the absence (.; n = 6) and presence (n = 3) of 0.1 
(e), 0.3 (~), 1 (+) and 3 (.6.)I'M 3b. (d) Schild regression from 
experiments in rabbit vas deferens (e), guinea-pig atria (.) and 
guinea-pig ileum smooth muscle (.6.). 
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Comparison of the binding and pharmacological 
properties 
The affinities of the compounds studied in this work for the 
M2 receptors in rat heart (binding) and guinea-pig atria 
(functional studies) were very similar, both individually and 
in rank order (Figure 6). The affinities of the compounds for 
the M3 receptors in rat pancreas (binding) were consistently 
2-3 fold less than in guinea-pig ileum (functional studies). 
This might explain part of the difference between the pKi and 
pA2 values of p-fluoro-sila-hexocyclium, which was 10 fold 
less potent in binding than in pharmacological studies on M3 
receptors. The binding affinities of most of the compounds 
for Ml receptors in rat cortex, human neuroblastoma (NB-
OK 1) cells and calf superior cervical ganglia were very close 
to their potencies obtained in pharmacological assays at Md 
M4-like heteroreceptors in rabbit vas deferens (Tables 1 and 2 
and Figure 6). However, o-methoxy-sila-hexocyclium (3b) 
had a significantly lower affinity in binding compared to 
pharmacological assays (see also Lambrecht e"t al., 1988; 
Boddeke et al., 1989; Polidori et al., 1990; Lazareno & 
Birdsall, 1993). This is particularly frustrating, since 0-
methoxy-sila-hexocyclium had a remarkable selectivity, in 
pharmacological studies, for the rabbit vas deferens and rat 
superior cervical ganglia receptors. It is noteworthy that the 
pA2 values obtained for hexocyclium (la; 8.89), sila-hexo-
cyclium (lb; 9.01), demethyl-sila-hexocyclium (2b; 7.73) and 
o-methoxy-sila-hexocyclium (3b; 8.39) in rabbit vas deferens 
(this study) were very similar to those at Ml receptors in rat 
superior cervical ganglia (Eltze et al., 1988; Lambrecht et al., 
1988: la = 8.8; lb = 9.6; 2b = 7.6; 3b = 8.3). In addition, the 
functional affinity of sila-hexocyclium (lb; pA2 = 8.78) for 
muscarinic M3 receptors in guinea-pig ileum (this study) was 
very close to reported M3 affinity data obtained in other 
tissues (rat parietal cells: Ki-[3H]-NMS binding = 3.2 nM; 
Ki-inositol phosphate production = 1.5 nM; Ki-[l4C]-amino-
pyrine accumulation = 2.7 nM; Pfeiffer et al., 1990b. Human 
HT-29 colon carcinoma cells: Ki-[3H]-NMS binding = 
3.1 nM; Kopp et al., 1989. Human gastric mucosa: Ki-eH]-
NMS binding = 5.6 nM; Pfeiffer et al., 1990a). 
We checked whether there could be an additional action of 
o-methoxy-sila-hexocyclium (other than on muscarinic recep-
tors) in rabbit vas deferens by measuring the dose-ratio for 
McN-A-343 in the presence either of pirenzepine, of 3b, or of 
a combination of the two antagonists. The results confirmed 
that there is no additional action of compound 3b which 
cannot be accounted for by a competitive mechanism of 
action. We then decided to compare its binding properties to 
several different Ml binding sites of different origins (different 
animal species and different rat brain regions), in the hope of 
finding an assay system with Ml receptors having a high 
affinity for 3b. However, the binding properties of piren-
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